Viyash Scientific Limited has submitted a regulatory disclosure to BSE Limited and National Stock Exchange of India Limited under SEBI Listing Regulation 30. This communication serves as an update regarding the proposed acquisition of 100% shareholding in BioForLife Italia S.r.l., Milan, Italy by Alivira Animal Health Limited, Ireland, which is a step-down wholly owned subsidiary of Viyash Scientific Limited.
The company confirms that requisite approval has been received from relevant Italian authorities in connection with applicable Italian FDI / Golden Power regulations. This represents a significant regulatory milestone for the transaction.
The expected timeline for completion of the transaction has been revised. Taking into account the remaining customary closing formalities and closing conditions, the transaction is now expected to be completed within two months from the date of this intimation (September 8, 2026).
All other material terms and conditions set out in the previous disclosures dated June 8, 2026 and July 21, 2026 remain unchanged. The company has requested the exchanges to take this update on record.
#ViyashScientific #BioForLifeAcquisition #SEBIRegulation30 #M&AUpdate #Neutral